TargeGen, Inc.
TargeGen is developing small molecule therapeutics to treat cancer and cardiovascular disease. The development-stage firm's lead drug candidate, TG 100-115, could prevent complications after heart attacks. Other therapies in TargeGen's pipeline include a potential treatment for colorectal cancer, non-small cell lung cancer, and macular degeneration, an eye condition that often leads to blindness. The biotech company had been eying an IPO but opted in mid-2005 to stay private and took on an additional round of venture capital financing to fund trials of TG 100-115.
Contact Details
Office Address
TargeGen, Inc.
9380 Judicial Drive
San Diego, CA, USA 92121
Phone: (858) 678-0760
Fax: (858) 678-0762
Executives
Chairman
Ivor Royston
President, CEO and Director
Peter G. Ulrich